Cardiovascular Diseases, Hypertrophic Cardiomyopathy (HCM), Other Hypoxic and Fibroblast Activated Diseases, Pulmonary Fibrosis, Rheumatic Immune Diseases Involving Large Blood Vessels, Tumor
Conditions
Brief summary
The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
Interventions
DRUGInjection of 68Ga-NI-FAPI
Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* 1: 18-85 years old 2: Tumor patients can undergo surgery or biopsy to obtain pathological diagnosis 3: Ability to understand and sign informed consent forms 4: Expected survival period exceeding 6 months and able to receive follow-up 5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc
Exclusion criteria
* 1: Pregnant or lactating women 2: Patients allergic to research drug ingredients 3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L) 4: Patients who participate in other clinical trials and interfere with the results of this study 5: Patients with severe illness who cannot cooperate with the examination
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04 | Within 30-120 minutes after intravenous injection of imaging agent | Semi quantitative analysis (measuring lesion standard uptake value (SUV), then calculating lesion SUV to liver/blood pool SUV ratio) |
Countries
China
Contacts
CONTACTZhu
Outcome results
None listed